Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ann Neurol ; 86(2): 168-180, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31177555

RESUMO

OBJECTIVE: Heightened somatic symptoms are reported by a wide range of patients with chronic pain and have been associated with emotional distress and physical dysfunction. Despite their clinical significance, molecular mechanisms leading to their manifestation are not understood. METHODS: We used an association study design based on a curated list of 3,295 single nucleotide polymorphisms mapped to 358 genes to test somatic symptoms reporting using the Pennebaker Inventory of Limbic Languidness questionnaire from a case-control cohort of orofacial pain (n = 1,607). A replication meta-analysis of 3 independent cohorts (n = 3,189) was followed by functional validation, including in silico molecular dynamics, in vitro enzyme assays, and measures of serotonin (5-HT) plasma concentration. RESULTS: An association with the T allele of rs11575542 coding for an arginine to glutamine substitution in the L-aromatic amino acid decarboxylase (AADC) enzyme was replicated in a meta-analysis of 3 independent cohorts. In a combined meta-analysis of all cohorts, this association reached p = 6.43 × 10-8 . In silico studies demonstrated that this substitution dramatically reduces the conformational dynamics of AADC, potentially lowering its binding capacity to a cofactor. in vitro enzymatic assays showed that this substitution reduces the maximum kinetic velocity of AADC, hence lowering 5-HT levels. Finally, plasma samples from 90 subjects showed correlation between low 5-HT levels and heightened somatic symptoms. INTERPRETATION: Using functional genomics approaches, we identified a polymorphism in the AADC enzyme that contributes to somatic symptoms through reduced levels of 5-HT. Our findings suggest a molecular mechanism underlying the pathophysiology of somatic symptoms and opens up new treatment options targeting the serotonergic system. ANN NEUROL 2019;86:168-180.


Assuntos
Substituição de Aminoácidos/genética , Descarboxilases de Aminoácido-L-Aromático/genética , Dor Facial/genética , Estudos de Associação Genética/métodos , Sintomas Inexplicáveis , Serotonina/genética , Adolescente , Adulto , Estudos de Casos e Controles , Dor Facial/diagnóstico , Feminino , Células HEK293 , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estrutura Secundária de Proteína , Transdução de Sinais/genética , Adulto Jovem
2.
Pain ; 160(4): 932-944, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30763288

RESUMO

Chronic pain is a debilitating and poorly treated condition whose underlying mechanisms are poorly understood. Nerve injury and inflammation cause alterations in gene expression in tissues associated with pain processing, supporting molecular and cellular mechanisms that maintain painful states. However, it is not known whether transcriptome changes can be used to reconstruct a molecular pathophysiology of pain. In the current study, we identify molecular pathways contributing to chronic pain states through the analysis of global changes in the transcriptome of dorsal root ganglia, spinal cord, brain, and blood in mouse assays of nerve injury- and inflammation-induced pain. Comparative analyses of differentially expressed genes identified substantial similarities between 2 animal pain assays and with human low-back pain. Furthermore, the extracellular matrix (ECM) organization has been found the most commonly regulated pathway across all tested tissues in the 2 animal assays. Examination of human genome-wide association study data sets revealed an overrepresentation of differentially expressed genes within the ECM organization pathway in single nucleotide polymorphisms most strongly associated with human back pain. In summary, our comprehensive transcriptomics analysis in mouse and human identified ECM organization as a central molecular pathway in the development of chronic pain.


Assuntos
Matriz Extracelular/genética , Matriz Extracelular/metabolismo , Inflamação/genética , Inflamação/patologia , Neuralgia/genética , Neuralgia/patologia , Animais , Modelos Animais de Doenças , Feminino , Adjuvante de Freund/toxicidade , Redes Reguladoras de Genes/genética , Estudos de Associação Genética , Testes Genéticos , Humanos , Inflamação/induzido quimicamente , Camundongos , Camundongos Endogâmicos BALB C , Medição da Dor , Polimorfismo de Nucleotídeo Único/genética , RNA Mensageiro/metabolismo , Transcriptoma/fisiologia
3.
Pain ; 159(4): 749-763, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29300278

RESUMO

The Human Pain Genetics Database (HPGDB) is a comprehensive variant-focused inventory of genetic contributors to human pain. After curation, the HPGDB currently includes 294 studies reporting associations between 434 distinct genetic variants and various pain phenotypes. Variants were then submitted to a comprehensive analysis. First, they were validated in an independent high-powered replication cohort by testing the association of each variant with 10 different pain phenotypes (n = 1320-26,973). One hundred fifty-five variants replicated successfully (false discovery rate 20%) in at least one pain phenotype, and the association P values of the HPGDB variants were significantly lower compared with those of random controls. Among the 155 replicated variants, 21 had been included in the HPGDB because of their association with analgesia-related and 13 with nociception-related phenotypes, confirming analgesia and nociception as pathways of vulnerability for pain phenotypes. Furthermore, many genetic variants were associated with multiple pain phenotypes, and the strength of their association correlated between many pairs of phenotypes. These genetic variants explained a considerable amount of the variance between different pairs of pain phenotypes, indicating a shared genetic basis among pain phenotypes. In addition, we found that HPGDB variants show many pleiotropic associations, indicating that genetic pathophysiological mechanisms are also shared among painful and nonpainful conditions. Finally, we demonstrated that the HPGDB data set is significantly enriched for functional variants that modify gene expression, are deleterious, and colocalize with open chromatin regions. As such, the HPGDB provides a validated data set that represents a valuable resource for researchers in the human pain field.


Assuntos
Bases de Dados Genéticas , Pleiotropia Genética/genética , Predisposição Genética para Doença/genética , Variação Genética/genética , Dor/genética , Feminino , Estudos de Associação Genética , Humanos , Masculino , PubMed/estatística & dados numéricos
4.
J Pain ; 16(12): 1321-1333, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26456674

RESUMO

UNLABELLED: Recent efforts have suggested that the ß-adrenergic receptor (ß-AR) system may be a novel and viable therapeutic target for pain reduction; however, most of the work to date has focused on the ß(2)-adrenergic receptor (AR). Here, we compared the antinociceptive effects of enantiomeric configurations of propranolol and bupranolol, two structurally similar nonselective ß-blocking drugs, against mouse models of inflammatory and chronic pain. In addition, we calculated in silico docking and measured the binding properties of propranolol and bupranolol for all 3 ß-ARs. Of the agents examined, S-bupranolol is superior in terms of its antinociceptive effect and exhibited fewer side effects than propranolol or its associated enantiomers. In contrast to propranolol, S-bupranolol exhibited negligible ß-AR intrinsic agonist activity and displayed a full competitive antagonist profile at ß(1)/ß(2)/ß(3)-ARs, producing a unique blockade of ß(3)-ARs. We have shown that S-bupranolol is an effective antinociceptive agent in mice without negative side effects. The distinctive profile of S-bupranolol is most likely mediated by its negligible ß-AR intrinsic agonist activity and unique blockade of ß(3)-AR. These findings suggest that S-bupranolol instead of propranolol may represent a new and effective treatment for a variety of painful conditions. PERSPECTIVE: The S enantiomer of bupranolol, a ß-receptor antagonist, shows greater antinociceptive efficacy and a superior preclinical safety profile and it should be considered as a unique ß-adrenergic receptor compound to advance future clinical pain studies.


Assuntos
Antagonistas Adrenérgicos beta/farmacologia , Analgésicos/farmacologia , Bupranolol/farmacologia , Nociceptividade/efeitos dos fármacos , Propranolol/farmacologia , Receptores Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/química , Analgésicos/química , Animais , Bupranolol/química , Modelos Animais de Doenças , Feminino , Masculino , Camundongos , Medição da Dor , Propranolol/química , Receptores Adrenérgicos beta/química , Estereoisomerismo
5.
Pain ; 156(10): 2072-2083, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26207649

RESUMO

Catechol-O-methyltransferase (COMT) metabolizes catecholaminergic neurotransmitters. Numerous studies have linked COMT to pivotal brain functions such as mood, cognition, response to stress, and pain. Both nociception and risk of clinical pain have been associated with COMT genetic variants, and this association was shown to be mediated through adrenergic pathways. Here, we show that association studies between COMT polymorphic markers and pain phenotypes in 2 independent cohorts identified a functional marker, rs165774, situated in the 3' untranslated region of a newfound splice variant, (a)-COMT. Sequence comparisons showed that the (a)-COMT transcript is highly conserved in primates, and deep sequencing data demonstrated that (a)-COMT is expressed across several human tissues, including the brain. In silico analyses showed that the (a)-COMT enzyme features a distinct C-terminus structure, capable of stabilizing substrates in its active site. In vitro experiments demonstrated not only that (a)-COMT is catalytically active but also that it displays unique substrate specificity, exhibiting enzymatic activity with dopamine but not epinephrine. They also established that the pain-protective A allele of rs165774 coincides with lower COMT activity, suggesting contribution to decreased pain sensitivity through increased dopaminergic rather than decreased adrenergic tone, characteristic of reference isoforms. Our results provide evidence for an essential role of the (a)-COMT isoform in nociceptive signaling and suggest that genetic variations in (a)-COMT isoforms may contribute to individual variability in pain phenotypes.


Assuntos
Catecol O-Metiltransferase/genética , Regulação da Expressão Gênica/genética , Limiar da Dor/fisiologia , Polimorfismo de Nucleotídeo Único/genética , Transtornos da Articulação Temporomandibular/genética , Encéfalo/metabolismo , Estudos de Casos e Controles , Catecol O-Metiltransferase/metabolismo , Linhagem Celular Tumoral , Estudos de Coortes , Feminino , Variação Genética , Humanos , Masculino , Neuroblastoma/patologia , Dor/etiologia , Dor/genética , Fenótipo , RNA Mensageiro/metabolismo , Transtornos da Articulação Temporomandibular/complicações , Transfecção
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...